5-溴-2-氯嘧啶-4-羧酸乙酯 | 1370725-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-2-氯嘧啶-4-羧酸乙酯
• 英文名称: ethyl 5-bromo-2-chloropyrimidine-4-carboxylate
• 英文别名: Ethyl 5-bromo-2-chloropyrimidine-4-carboxylate
• CAS: 1370725-06-6
• 化学式: C₇H₆BrClN₂O₂
• 分子量: 265.494
• InChiKey: HWIFHRPCOIMPMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-溴-2-氯嘧啶-4-羧酸乙酯 在 N-碘代丁二酰亚胺 、 palladium diacetate 、 caesium carbonate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-chloro-N-[(2S)-2,3-dihydroxypropyl]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors

  摘要：

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.086
• 作为产物：
  描述：

  丙酮酸乙酯 、 5-溴-2-氯嘧啶 在 ferrous(II) sulfate heptahydrate 、 硫酸 、 双氧水 、 溶剂黄146 作用下， 以 水 、 甲苯 为溶剂， 反应 1.5h， 生成 5-溴-2-氯嘧啶-4-羧酸乙酯
  参考文献：
  名称：

  [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
  [FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B

  摘要：

  该申请描述了二氢嘧啶衍生物，其在治疗或预防HBV感染或HBV引起的疾病中是有用的，尤其是HBV慢性感染或由HBV慢性感染引起的疾病，以及它们的药物或医疗应用。

  公开号：

  WO2020001448A1

文献信息

• [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES<br/>[FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020001448A1

  公开（公告）日：2020-01-02

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了二氢嘧啶衍生物，其在治疗或预防HBV感染或HBV引起的疾病中是有用的，尤其是HBV慢性感染或由HBV慢性感染引起的疾病，以及它们的药物或医疗应用。
• Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11053235B2

  公开（公告）日：2021-07-06

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病，特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物，以及其在制药或医疗方面的应用。
• DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：EP3814326A1

  公开（公告）日：2021-05-05
• [EN] PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE<br/>[FR] DÉRIVÉS DE PYRROLIDINONE UTILES COMME INHIBITEURS DE LA KINASE D'INDUCTION DE NF-KB
  申请人：[en]JANSSEN PHARMACEUTICA NV

  公开号：WO2023217906A1

  公开（公告）日：2023-11-16

  The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as inflammatory disorders and autoimmune disorders.
• Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors
  作者：Hejun Lu、Wangyang Tu、Hongbo Fei、Guoji Xu、Qiyue Hu、Lei Zhang、Bing Lin、Jijun Yuan、Junzhao Yin、Aishen Gong、Mimi Wan、Dan Wang、Xiaoyan Zhu、Jun Feng、Qian Wang、Piaoyang Sun

  DOI：10.1016/j.bmcl.2014.03.086

  日期：2014.6

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.